Molecular Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2023-09-01 ms9508293866653270 来自陕西省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。

105 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2023-11-12 wym0577 来自浙江省

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-03-10 1811e984f8m 来自安徽省

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤;肿瘤化疗
经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。

33 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-01-10 1464d723m79暂无昵称来自广东省

Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？

36 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-03-19 ms7000000762441132 来自河南省

审稿速度:3.0
偏重的研究方向：cancer
经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers.

16 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-04-22 a201061519 来自河南省

偏重的研究方向：肿瘤
经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2021-07-27 Medicalresearch

under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢

91 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-01-21 ms9000001581615796 来自江苏省

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修

31 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2024-01-08 P拾荒者来自浙江省

偏重的研究方向：肿瘤生物学
经验分享：1.7投了一篇综述，看看多久拒稿

28 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2192414, encodeId=15d72192414e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤;肿瘤化疗 经验分享：现在硬投一篇molecular cancer research系列文章已经相当不容易了。当然，该杂志上面还有一些no ncoding RNA的关系稿，水平很低。虽说大CDD，nature com，j of hepatology, cancer research，advanced science等也时不时也些关系稿，但文章水平也差不了太多。就这点，希望molecular cancer杂志能过改进。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Mar 10 19:25:13 CST 2024, time=2024-03-10, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2180553, encodeId=7b172180553ec, content=Editor appointed一个月了，大家有遇到这种情况吗，是稿件太多了处理不过来吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f8c5128063, createdName=1464d723m79暂无昵称, createdTime=Wed Jan 10 19:12:54 CST 2024, time=2024-01-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194122, encodeId=7b5e21941225e, content=审稿速度:3.0 偏重的研究方向：cancer 经验分享：圣诞节前投的，三个月还是peer review，具体显示The editors' decision can take several weeks as they may consult peer reviewers., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2069031093, createdName=ms7000000762441132, createdTime=Tue Mar 19 17:13:04 CST 2024, time=2024-03-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2199853, encodeId=dbe82199853f2, content=偏重的研究方向：肿瘤 经验分享：各位大牛们！这个期刊送审没有变化吗？一直是peer review 状态，怎么知道是不是送审了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Mon Apr 22 21:35:59 CST 2024, time=2024-04-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2179973, encodeId=b37d21e9973ad, content=偏重的研究方向：肿瘤生物学 经验分享：1.7投了一篇综述，看看多久拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 08 15:19:18 CST 2024, time=2024-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省)]

2023-01-05 ms4000001414066014 来自河南省

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：circRNA
经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了

92 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务